Plasma Cell Leukemia vs. Multiple Myeloma

Plasma cell leukemia (PCL) is the most aggressive form of plasma cell cancer, distinguished from multiple myeloma (MM) by the presence of malignant plasma cells circulating freely in the bloodstream rather than staying confined to the bone marrow. While myeloma cells typically anchor themselves inside bone marrow, PCL cells break loose and flood the peripheral blood, producing a disease that behaves more like a fast-moving leukemia than a slow-building marrow cancer. The distinction matters enormously for prognosis: even with modern treatments, median survival for PCL patients remains a fraction of what myeloma patients can expect.

Where the Line Is Drawn

For decades, the dividing line between myeloma and PCL was set at 20% circulating plasma cells in a peripheral blood smear, a threshold established in 1974. That cutoff stood for nearly half a century. But accumulating evidence showed that patients with much lower levels of circulating plasma cells already had outcomes just as grim as those meeting the old 20% bar. In 2021, the International Myeloma Working Group formally lowered the diagnostic threshold to 5% or more circulating plasma cells in peripheral blood smears in patients who otherwise meet the criteria for symptomatic myeloma.¹

This was not a small administrative tweak. A Mayo Clinic study comparing patients diagnosed after 2001 found that those with 5% or more circulating plasma cells had a median overall survival of about 1.4 years, compared with roughly 5.7 years for myeloma patients in the same treatment era. Even when compared to high-risk myeloma specifically, the PCL group fared significantly worse.² The threshold change effectively reclassified a group of myeloma patients as PCL patients, acknowledging that their disease was already behaving like leukemia even at relatively low circulating cell counts.

Research has pushed the boundary even further. One study found that having more than 2% circulating tumor plasma cells was enough to identify a group with PCL-like outcomes, suggesting that even the new 5% threshold may still miss some patients whose disease has already taken on leukemic characteristics.³ Where exactly the line should fall remains an active question, but the direction of the evidence is clear: lower thresholds catch more patients whose biology is genuinely leukemic.

Primary Versus Secondary PCL

Not all plasma cell leukemia arrives the same way. Primary PCL (pPCL) appears at first diagnosis, without any prior history of myeloma. Secondary PCL (sPCL) develops as a late transformation in someone who already has myeloma, typically after multiple rounds of treatment. The two forms share the same defining feature of circulating plasma cells, but they differ sharply in their outlook.

A large US cohort study found median overall survival of about 37 months for primary PCL but only 3.2 months for secondary PCL.⁴ A separate European study reported an even starker gap: roughly 18 months for primary and just 1.2 months for secondary.⁵ The variation between studies reflects differences in patient populations and treatment access, but the pattern is consistent: secondary PCL is among the most rapidly fatal blood cancers.

The reason secondary PCL is so much worse relates to what the cancer has already been through. By the time myeloma transforms into overt leukemia, the tumor has typically survived multiple lines of therapy, accumulating resistance along the way. Primary PCL, while still aggressive, is at least treatment-naïve. That gives clinicians a wider window to try intensive regimens before resistance sets in.

Why Myeloma Cells Stay Put and Leukemia Cells Do Not

In typical myeloma, plasma cells are tethered inside the bone marrow by adhesion molecules on their surface. These are molecular anchors that stick to stromal cells and the surrounding matrix, keeping the malignant cells in place. The key difference in PCL is that many of these anchors are weakened or lost. Studies comparing the surface markers of bone marrow plasma cells in myeloma patients with and without circulating cells found significant decreases in several adhesion molecules, including CD49d, CD49e, CD56, and CD138, in patients whose cells had entered the bloodstream. The circulating cells themselves showed even further loss of these molecules.⁶

CD56 appears to be especially important. An early flow cytometry study found that CD56 expression on myeloma cells was inversely related to how many plasma cells appeared in the blood: the lower the CD56, the more circulating cells.⁷ Roughly one-third of PCL cases express CD56 at all, compared with the majority of standard myeloma cases.⁸ Think of it as the cancer cells shedding their velcro. Once enough adhesion is lost, the cells detach from the marrow niche and drift into the bloodstream, where they can seed damage in the spleen, liver, and elsewhere.

Genetic Landscape and What It Means for Aggressiveness

PCL is not just myeloma with a few extra circulating cells. Genetically, it looks different. Primary PCL carries a much higher frequency of cytogenetic abnormalities that are already considered high-risk in myeloma but occur at rates two to three times greater. One large genomic study found deletion of the short arm of chromosome 17, called del(17p), in about 30% of primary PCL compared with roughly 10% in myeloma. Gain of chromosome 1q was present in about 53% versus 32%, and deletion of 1p32 appeared in about 24% versus 9%.⁹

These abnormalities are not just bookkeeping. Del(17p), for instance, knocks out the TP53 tumor suppressor gene, one of the cell’s most important brakes on uncontrolled growth. When that brake fails, the cancer becomes harder to kill with standard therapy and more prone to relapse. The clustering of multiple high-risk hits in PCL helps explain why the disease resists treatments that work reasonably well in standard-risk myeloma.

Going a step further, researchers have used gene expression data to build a transcriptomic classifier that can identify “PCL-like” myeloma, meaning myeloma that genetically and transcriptionally resembles PCL even though its circulating cell count has not yet crossed the diagnostic threshold. This classifier found that roughly 10% of newly diagnosed myeloma tumors had PCL-like gene expression patterns, and those patients had outcomes that tracked closer to PCL than to typical myeloma.¹⁰ This raises the possibility that one day a gene signature, not just a cell count, could identify patients who need PCL-intensity treatment from the start.

How Myeloma Transforms Into Leukemia Over Time

For secondary PCL, the transformation from myeloma to overt leukemia is not a single dramatic event. Whole-genome sequencing of one patient tracked from initial myeloma diagnosis through relapse to secondary PCL and found that the tumor was heterogeneous from the very beginning. Multiple related but distinct clones existed at diagnosis, rising and falling in dominance over time as the patient underwent treatment. At the final PCL stage, several newly acquired mutations appeared, including truncating mutations in the RB1 tumor suppressor gene, that were not present earlier in the disease course.¹¹

The picture that emerges is of a tumor ecosystem under selective pressure from therapy. Some clones are killed, others survive and expand, and eventually a subclone with enough accumulated damage, enough lost adhesion molecules, and enough resistance mutations takes over and escapes the marrow entirely. This understanding has implications for treatment: by the time transformation happens, the surviving cancer is often resistant to everything the patient has already received, which is a major reason secondary PCL carries such a dismal prognosis.

Clinical Presentation and What Patients Experience

Myeloma and PCL share certain features: bone pain, anemia, kidney damage, and elevated levels of abnormal immunoglobulin in the blood. But PCL tends to present more explosively. Thrombocytopenia, meaning dangerously low platelet counts, is common and often severe, leading to bleeding complications. Splenomegaly (an enlarged spleen) occurs frequently in PCL and is uncommon in standard myeloma. Both primary and secondary PCL also show a higher proportion of light-chain-only disease, where the malignant cells produce incomplete antibody fragments rather than the full immunoglobulin molecules more common in myeloma.¹²

Extramedullary disease, where plasma cell tumors grow in soft tissue, the liver, lymph nodes, or even the central nervous system, is another feature that distinguishes aggressive PCL from typical myeloma. While extramedullary disease occurs in a small minority of myeloma cases at diagnosis, its frequency rises in relapsed and refractory settings and is relatively common in PCL. In some cases, patients present with extramedullary masses as their most prominent symptom, even before the diagnosis is fully worked out.

Hyperviscosity syndrome, where the sheer volume of abnormal protein in the blood makes it too thick to flow properly, can also occur and represents a medical emergency. When it does appear, emergency plasma exchange can produce rapid improvement.¹³

Treatment of Primary PCL

Because PCL is so rare, no large randomized trials have been completed specifically for this disease. Treatment strategies have been adapted from myeloma regimens, with the general principle that more intensive therapy upfront produces better results than in standard myeloma, where gentler approaches sometimes suffice.

The most encouraging recent data come from studies of modern combination regimens. A multicenter Greek study evaluated bortezomib-lenalidomide-dexamethasone triplets (VRd) and daratumumab-based quadruplets against older bortezomib combinations and conventional chemotherapy. The newer regimens doubled complete response rates (about 41% versus 17%) and dramatically improved survival. Median progression-free survival was roughly 25 months with VRd or daratumumab-based quadruplets, compared with 13 months for older regimens. Three-year overall survival reached 70% in the modern-regimen group versus 32% in the older-treatment group.¹⁴

Stem cell transplantation remains a central part of management for eligible patients. Transplant was associated with a survival advantage in both primary and secondary PCL in the US cohort study.¹⁵ However, even with transplant, the duration of response is notably shorter than it is for myeloma. One analysis showed that PCL patients were actually more likely to achieve complete remission after autologous transplant than myeloma patients, but their overall survival was still far inferior (about 26 months versus 62 months) because responses did not last and because non-relapse mortality was higher.¹⁶

The Transplant Strategy Debate

Whether to pursue an allogeneic transplant (using a donor’s cells) rather than the standard autologous approach (using the patient’s own cells) is one of the open questions in PCL management. An allogeneic transplant offers the potential benefit of a graft-versus-myeloma immune effect, where the donor’s immune system can attack remaining cancer cells. The trade-off is substantially higher treatment-related mortality.

A study comparing strategies found that patients who went directly to an allogeneic transplant had a lower relapse rate at three years (about 46% versus 68%) but much higher non-relapse mortality (27% versus 7%). In the first 100 days after transplant, the risk of dying was markedly higher with the allogeneic-first approach. A potentially attractive middle ground was a tandem strategy: autologous transplant first, followed by an allogeneic transplant. Patients who followed the auto-then-allo path had no excess early risk and showed a significant improvement in progression-free survival after the first 100 days compared with patients who received a single autologous transplant alone.¹⁷

A smaller study that directly compared autologous and allogeneic transplant outcomes in the modern treatment era found no statistically significant survival advantage for the allogeneic approach, with relapse remaining the primary cause of death regardless of transplant type.¹⁸ The field has not settled this question, and decisions tend to be made case by case, weighing the patient’s age, fitness, donor availability, and how well they responded to initial treatment.

Bispecific Antibodies and Emerging Immunotherapy

Some of the most anticipated advances in myeloma treatment are immunotherapies, particularly bispecific antibodies that redirect a patient’s own immune cells to attack cancer cells. These drugs have shown impressive results in relapsed myeloma, but their performance in PCL has been less straightforward.

A real-world study evaluated several bispecific antibodies in PCL patients. The overall response rate across the group was about 55%, but outcomes varied sharply by drug. Talquetamab, which targets a protein called GPRC5D, performed best, with responses in roughly 60% of patients and median progression-free survival of about 5.5 months when used as a line of therapy. By contrast, teclistamab and elranatamab, which target a different protein called BCMA, had significantly shorter progression-free survival of around 1 to 2 months and worse overall survival.¹⁹

Why GPRC5D-targeted therapy outperformed BCMA-targeted therapy in PCL is not fully understood, but one possibility relates to how PCL cells express these target molecules. BCMA can be shed from the cell surface and is found at high levels in the blood of patients with heavy disease burden, which may interfere with drug binding. Regardless of the mechanism, these early results suggest that not all immunotherapies will work equally well when myeloma crosses the leukemia threshold, and target selection may matter more in PCL than in myeloma.

The Blurry Boundary and PCL-Like Myeloma

One of the more uncomfortable realities in this field is that the boundary between myeloma and PCL is not a clean biological line. It is a diagnostic threshold imposed on a continuous spectrum. Some myeloma patients with very few circulating plasma cells carry the same genetic profile and gene expression pattern seen in frank PCL. As noted earlier, transcriptomic classifiers identify about 10% of newly diagnosed myeloma cases as biologically PCL-like, even though they do not meet the circulating cell threshold for a PCL diagnosis.²⁰

This has practical consequences. A patient classified as having high-risk myeloma might actually have a disease that is, at a molecular level, already leukemic. They may benefit from more aggressive upfront treatment than a standard high-risk myeloma protocol provides, but current clinical guidelines do not routinely incorporate transcriptomic classification into treatment decisions. The gap between what the science can identify and what clinical practice acts on is one of the frustrations in this space. Meanwhile, the lowering of the diagnostic threshold from 20% to 5% circulating plasma cells has already reclassified some patients, and the data suggesting that even 2% may be meaningful continues to push the boundary further.²¹

For patients and families, the key takeaway is that a myeloma diagnosis does not guarantee the disease will stay in the marrow, and a handful of circulating plasma cells on a blood test may signal something more serious than the old classification system would have recognized. Conversely, a PCL diagnosis today captures a wider group of patients than it did before 2021, meaning some recently diagnosed PCL patients have a disease that would have been labeled aggressive myeloma just a few years ago. Whether the relabeling leads to meaningfully different treatment, or simply a different prognosis conversation, depends on the treating center and the evolving guidelines.

How Survival Numbers Compare Side by Side

Putting the survival data into perspective helps clarify just how different these diseases behave. In the modern treatment era, standard-risk myeloma patients have a median survival that can exceed seven years, and high-risk myeloma patients can expect roughly four to five years.²² Primary PCL, when treated with modern regimens including bortezomib-lenalidomide combinations or daratumumab-based quadruplets, now shows three-year survival rates approaching 70% in some series, a meaningful improvement over the roughly 30% three-year survival seen with older regimens.²³ Secondary PCL remains profoundly difficult to treat, with median survival measured in weeks to a few months.

These numbers underscore why early and accurate identification matters. A myeloma patient with 5% circulating plasma cells who is treated as standard high-risk myeloma rather than PCL may not receive the transplant consolidation or the more intensive induction that the disease warrants. As the diagnostic criteria continue to evolve and molecular profiling becomes more accessible, the hope is that treatment intensity can be better matched to the biology of each patient’s cancer rather than a single threshold number.

How Rare Is PCL

PCL is uncommon even among blood cancers. Primary PCL represents roughly 2 to 5% of all plasma cell neoplasms, though recent reclassification under the lower threshold may shift reported incidence upward. Secondary PCL develops in up to 2% of myeloma patients over the course of their disease, though this figure may also be rising as improved treatments extend myeloma survival and better diagnostics catch cases that would have been missed previously.

The rarity creates a persistent problem for research. It is extremely difficult to run the kind of large randomized controlled trials that have transformed treatment for myeloma itself. Most of what is known about PCL treatment comes from retrospective cohort studies, registry analyses, and subgroup data from myeloma trials. This means treatment recommendations are based on weaker evidence than many clinicians or patients would like, and the field relies heavily on extrapolation from myeloma data combined with the clinical experience of specialist centers that see enough PCL cases to recognize patterns.